Company Filing History:
1 out of 575 
1 out of 223 
Years Active: 2025
Title: Kenichi Koda: Innovator in Cancer Treatment
Introduction
Kenichi Koda is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of cancer treatment, particularly in the development of biomarkers for immune checkpoint inhibitors. His work aims to enhance the effectiveness of cancer therapies and improve patient outcomes.
Latest Patents
Kenichi Koda holds a patent for a method that identifies patients with malignant tumors who are likely to benefit from immune checkpoint inhibitors. This innovative approach involves analyzing various evaluation items, including the intensity of PD-1 expression and the percentage of PD-1 expressing cells in Treg and CD8T cells within tumor tissue or blood. His patent is titled "Biomarkers for determining the effectiveness of immune checkpoint inhibitors."
Career Highlights
Throughout his career, Koda has worked with notable organizations, including Ono Pharmaceutical Co., Ltd. and the National Cancer Center. His experience in these institutions has allowed him to contribute to groundbreaking research in oncology and immunotherapy.
Collaborations
Kenichi Koda has collaborated with esteemed colleagues such as Hiroyoshi Nishikawa and Yosuke Togashi. These partnerships have furthered his research and development efforts in the field of cancer treatment.
Conclusion
Kenichi Koda's innovative work in identifying biomarkers for immune checkpoint inhibitors represents a significant advancement in cancer therapy. His contributions continue to impact the medical community and improve treatment options for patients with malignant tumors.